A Phase I/II Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors).
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2014
At a glance
- Drugs Linsitinib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 07 Jun 2017 Biomarkers information updated
- 06 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.